| Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM (NCT06255847) | Shanxi Bethune Hospital | 2022-06-15 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma (NCT05121103) | Epizyme, Inc. | 2022-05-31 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies (NCT05191472) | Alfred Chung, MD | 2022-05-03 |
| APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma (NCT04657861) | Zhejiang University | 2022-05-03 |
| Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (NCT04925193) | University of Colorado, Denver | 2021-11-18 |
| TriPRIL CAR T Cells in Multiple Myeloma (NCT05020444) | Marcela V. Maus, M.D.,Ph.D. | 2021-10-05 |
| Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma (NCT04861480) | Chongqing Precision Biotech Co., Ltd | 2021-06-16 |
| A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (NCT04688853) | Gadeta B.V. | 2021-05-13 |
| Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells (NCT04813653) | Tel-Aviv Sourasky Medical Center | 2021-04-18 |
| Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (NCT04790474) | Tel-Aviv Sourasky Medical Center | 2021-03-25 |
| a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04776330) | Chongqing Precision Biotech Co., Ltd | 2021-03-07 |
| CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies (NCT04603872) | Zhejiang University | 2020-11-01 |
| Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma (NCT04287855) | Poitiers University Hospital | 2020-08-28 |
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM (NCT04176718) | Andrew Yee, MD | 2020-05-18 |
| Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (NCT04184050) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-04-13 |
| Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (NCT04272151) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| Ixazomib + Pomalidomide + Dexamethasone In MM (NCT04094961) | Omar Nadeem, MD | 2019-09-18 |
| Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (NCT03836014) | Assistance Publique - Hôpitaux de Paris | 2019-07-25 |
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma (NCT04162353) | iCell Gene Therapeutics | 2019-07-01 |
| A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT03650491) | Fortis Therapeutics, Inc. | 2019-04-03 |
| BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease (NCT04271644) | Chongqing Precision Biotech Co., Ltd | 2019-04-01 |
| TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03952091) | TJ Biopharma Co., Ltd. | 2019-03-27 |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma (NCT03777410) | Travera Inc | 2019-02-11 |
| TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03860038) | TJ Biopharma Co., Ltd. | 2019-01-28 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (NCT03428373) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-01-17 |
| Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma (NCT04065308) | Seoul National University Hospital | 2019-01-14 |
| A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma (NCT03697629) | Canadian Myeloma Research Group | 2018-12-03 |
| Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM (NCT03706547) | Peng Liu | 2018-10-30 |
| Tinostamustine Conditioning and Autologous Stem Cell (NCT03687125) | Mundipharma-EDO GmbH | 2018-10-15 |
| Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (NCT03601624) | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | 2018-09-01 |
| CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma (NCT03672253) | Second Affiliated Hospital of Xi'an Jiaotong University | 2018-07-26 |
| Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma (NCT03767725) | Shenzhen Second People's Hospital | 2018-06-02 |
| Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma (NCT03266692) | Cogent Biosciences, Inc. | 2018-02-22 |
| Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma (NCT03030261) | Washington University School of Medicine | 2017-11-22 |
| Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines (NCT03155100) | Raija Silvennoinen | 2017-08-07 |
| Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma (NCT04063189) | The First Hospital of Jilin University | 2017-03-21 |
| Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients (NCT02970747) | iOMEDICO AG | 2016-10-25 |
| Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients (NCT02981199) | Chen Wenming | 2016-01-01 |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (NCT01889420) | New Mexico Cancer Research Alliance | 2014-07-01 |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NCT02103335) | Celgene | 2014-06-05 |
| Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT02176213) | Ajai Chari | 2014-06-01 |
| Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma (NCT02004275) | Alliance for Clinical Trials in Oncology | 2014-02-01 |
| A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma (NCT01965353) | Dana-Farber Cancer Institute | 2013-10-01 |
| Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse (NCT01794572) | Institut Cancerologie de l'Ouest | 2013-04-09 |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma (NCT01329289) | University of Pittsburgh | 2011-12-01 |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) (NCT01435720) | Senesco Technologies, Inc. | 2011-09-01 |
| Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (NCT01394354) | University Hospital Freiburg | 2011-08-01 |
| Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (NCT01083602) | Novartis Pharmaceuticals | 2010-06-01 |
| Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients (NCT00401011) | AEterna Zentaris | 2006-08-01 |
| GO-203-2C + Bortezomib For Relapsed Or Refractory MM (NCT02658396) | Dana-Farber Cancer Institute | |
| Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma (NCT02666209) | Dana-Farber Cancer Institute | |